Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2015, Article ID 471283, 10 pages
http://dx.doi.org/10.1155/2015/471283
Research Article

Preparation and Evaluation of PEGylated and Folate-PEGylated Liposomes Containing Paclitaxel for Lymphatic Delivery

1College of Pharmacy, CHA University, Seongnam-si 463-712, Republic of Korea
2Department of Medical Management, Chodang University, Muan 534-701, Republic of Korea
3College of Pharmacy, Chonnam National University, Gwangju 500-757, Republic of Korea

Received 19 September 2014; Accepted 24 November 2014

Academic Editor: Sabine Szunerits

Copyright © 2015 Hea-Young Cho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Wall and M. C. Wani, “Camptothecin and taxol: from discovery to clinic,” Journal of Ethnopharmacology, vol. 51, no. 1–3, pp. 239–254, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. J. G. Kuhn, “Pharmacology and pharmacokinetics of paclitaxel,” Annals of Pharmacotherapy, vol. 28, no. 5, pp. S15–S17, 1994. View at Google Scholar · View at Scopus
  3. F. A. Fitzpatrick and R. Wheeler, “The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents,” International Immunopharmacology, vol. 3, no. 13-14, pp. 1699–1714, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. K. A. Kurdziel, D. O. Kiesewetter, R. E. Carson, W. C. Eckelman, and P. Herscovitch, “Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates,” Journal of Nuclear Medicine, vol. 44, no. 8, pp. 1330–1339, 2003. View at Google Scholar · View at Scopus
  5. L.-Q. Yang, B. Wang, H. Gan et al., “Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo,” Biopharmaceutics and Drug Disposition, vol. 33, no. 8, pp. 425–436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Engblom, J. O. Pulkkinen, V. Rantanen et al., “Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis,” European Journal of Cancer, vol. 35, no. 2, pp. 284–288, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Szebeni, F. M. Muggia, and C. R. Alving, “Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study,” Journal of the National Cancer Institute, vol. 90, no. 4, pp. 300–306, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom, “Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation,” European Journal of Cancer, vol. 37, no. 13, pp. 1590–1598, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. G. J. Fetterly and R. M. Straubinger, “Pharmacokinetics of paclitaxel-containing liposomes in rats,” AAPS PharmSciTech, vol. 5, no. 5, pp. 90–100, 2003. View at Google Scholar · View at Scopus
  10. T. Yang, F.-D. Cui, M.-K. Choi et al., “Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation,” International Journal of Pharmaceutics, vol. 338, no. 1-2, pp. 317–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-S. Choi and S.-C. Shin, “Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats,” International Journal of Pharmaceutics, vol. 292, no. 1-2, pp. 149–156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Azouz, J. Walpole, S. Amirifeli, K. N. Taylor, M. W. Grinstaff, and Y. L. Colson, “Prevention of local tumor growth with paclitaxel-loaded microspheres,” Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 5, pp. 1014–1021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Guo and C. C. Chu, “Biodegradable and injectable paclitaxel-loaded poly(ester amide)s microspheres: fabrication and characterization,” Journal of Biomedical Materials Research Part B Applied Biomaterials, vol. 89, no. 2, pp. 491–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Suh, B. Jeong, R. Rathi, and S. W. Kim, “Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly (ethylene oxide)-poly (lactide/glycolide) nanospheres,” Journal of Biomedical Materials Research Part A, vol. 42, no. 2, pp. 331–338, 1998. View at Google Scholar
  15. S.-S. Feng and G. Huang, “Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers,” Journal of Controlled Release, vol. 71, no. 1, pp. 53–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Yang, R. N. Gursoy, G. Lambert, and S. Benita, “Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors,” Pharmaceutical Research, vol. 21, no. 2, pp. 261–270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Zhao, H. Wang, M. Yu et al., “Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 2, pp. 248–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Zabaleta, G. Ponchel, H. Salman, M. Agüeros, C. Vauthier, and J. M. Irache, “Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 3, pp. 514–523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Torne, K. A. Ansari, P. R. Vavia, F. Trotta, and R. Cavalli, “Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges,” Drug Delivery, vol. 17, no. 6, pp. 419–425, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Mognetti, A. Barberis, S. Marino et al., “In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 74, no. 1–4, pp. 201–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. V. S. Varma and R. Panchagnula, “Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo,” European Journal of Pharmaceutical Sciences, vol. 25, no. 4-5, pp. 445–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. Kingsley, H. Dou, J. Morehead, B. Rabinow, H. E. Gendelman, and C. J. Destache, “Nanotechnology: a focus on nanoparticles as a drug delivery system,” Journal of Neuroimmune Pharmacology, vol. 1, no. 3, pp. 340–350, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. X. Song, V. Labhasetwar, H. Murphy et al., “Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery,” Journal of Controlled Release, vol. 43, no. 2, pp. 197–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Brigger, C. Dubernet, and P. Couvreur, “Nanoparticles in cancer therapy and diagnosis,” Advanced Drug Delivery Reviews, vol. 54, no. 5, pp. 631–651, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. R. H. Muller and C. M. Keck, “Challenges and solutions for the delivery of biotech drugs: a review of drug nanocrystal technology and lipid nanoparticles,” Journal of Biotechnology, vol. 113, no. 1–3, pp. 151–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Blume and G. Cevc, “Liposomes for the sustained drug release in vivo,” Biochimica et Biophysica Acta—Biomembranes, vol. 1029, no. 1, pp. 91–97, 1990. View at Publisher · View at Google Scholar · View at Scopus
  27. A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang, “Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes,” FEBS Letters, vol. 268, no. 1, pp. 235–237, 1990. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Weitman, R. H. Lark, L. R. Coney et al., “Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues,” Cancer Research, vol. 52, no. 12, pp. 3396–3401, 1992. View at Google Scholar · View at Scopus
  29. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, and M. Boiocchi, “Overexpression of folate binding protein in ovarian cancers,” International Journal of Cancer, vol. 74, no. 2, pp. 193–198, 1997. View at Google Scholar
  30. A. Gabizon, H. Shmeeda, A. T. Horowitz, and S. Zalipsky, “Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates,” Advanced Drug Delivery Reviews, vol. 56, no. 8, pp. 1177–1192, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. A. R. Hilgenbrink and P. S. Low, “Folate receptor-mediated drug targeting: from therapeutics to diagnostics,” Journal of Pharmaceutical Sciences, vol. 94, no. 10, pp. 2135–2146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Saul, A. Annapragada, J. V. Natarajan, and R. V. Bellamkonda, “Controlled targeting of liposomal doxorubicin via the folate receptor in vitro,” Journal of Controlled Release, vol. 92, no. 1-2, pp. 49–67, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, H. Shmeeda, and S. Zalipsky, “In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice,” Clinical Cancer Research, vol. 9, no. 17, pp. 6551–6559, 2003. View at Google Scholar · View at Scopus
  34. P. J. Stevens, M. Sekido, and R. J. Lee, “A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug,” Pharmaceutical Research, vol. 21, no. 12, pp. 2153–2157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. H. S. Yoo and T. G. Park, “Folate receptor targeted biodegradable polymeric doxorubicin micelles,” Journal of Controlled Release, vol. 96, no. 2, pp. 273–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Wu, Q. Liu, and R. J. Lee, “A folate receptor-targeted liposomal formulation for paclitaxel,” International Journal of Pharmaceutics, vol. 316, no. 1-2, pp. 148–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. R. J. Lee and P. S. Low, “Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1233, no. 2, pp. 134–144, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, and Y. Kawashima, “Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes,” Pharmaceutical Research, vol. 13, no. 6, pp. 896–901, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Yoshida, N. Oide, T. Sakamoto et al., “Induction of cancer cell-specific apoptosis by folate-labeled cationic liposomes,” Journal of Controlled Release, vol. 111, no. 3, pp. 325–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. S. Shord and J. R. Camp, “Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?” Biopharmaceutics and Drug Disposition, vol. 27, no. 4, pp. 191–196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Coudoré, N. Authier, D. Guillaume, A. Béal, E. Duroux, and J. Fialip, “High-performance liquid chromatographic determination of paclitaxel in rat serum: application to a toxicokinetic study,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 721, no. 2, pp. 317–320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Mohamed, P. Marchettini, O. A. Stuart, and P. H. Sugarbaker, “Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions,” Cancer Chemotherapy and Pharmacology, vol. 52, no. 5, pp. 405–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-S. Choi and X. Li, “The effect of verapamil on the pharmacokinetics of paclitaxel in rats,” European Journal of Pharmaceutical Sciences, vol. 24, no. 1, pp. 95–100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. “Guidance for industry, Bioanalytical method validation,” U.S. Food, Drug Administration, 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
  45. WinNonlin, User's Guide Ver. 3.0, Pharsight Corp., Mountain View, Calif, USA, 1999.
  46. M. Gibaldi and D. Perrier, Pharmacokinetics, Marcel Dekker, New York, NY, USA, 2nd edition, 1982.
  47. K. Moribe, K. Maruyama, and M. Iwatsuru, “Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives,” International Journal of Pharmaceutics, vol. 188, no. 2, pp. 193–202, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Silvander, M. Johnsson, and K. Edwards, “Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum,” Chemistry and Physics of Lipids, vol. 97, no. 1, pp. 15–26, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. J.-Y. Fang, “Nano- or submicron-sized liposomes as carriers for drug delivery,” Chang Gung Medical Journal, vol. 29, no. 4, pp. 358–362, 2006. View at Google Scholar · View at Scopus
  50. H. Chen, Z. Zhang, C. McNulty et al., “A high-throughput combinatorial approach for the discovery of a Cremophor EL-free paclitaxel formulation,” Pharmaceutical Research, vol. 20, no. 8, pp. 1302–1308, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Yang, M.-K. Choi, F.-D. Cui et al., “Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome,” Journal of Controlled Release, vol. 120, no. 3, pp. 169–177, 2007. View at Publisher · View at Google Scholar · View at Scopus